rejuvinated cd8 t-cells derived from ipscs in the treatment of myeloma
Published 2 years ago • 96 plays • Length 4:36Download video MP4
Download video MP3
Similar videos
-
0:52
developments in the treatment of myeloma
-
1:10
latest developments in the treatment of emd in myeloma
-
1:53
the future of multiple myeloma treatment
-
3:27
car-t cells in myeloma
-
2:30
a new era of treatment for multiple myeloma
-
1:03
harnessing the benefits of cd34 cells collected for double hsct in patients with multiple myeloma
-
21:38
drawing the line: the rationale behind blood tube collection order
-
4:04
the future of myeloma treatment and the possibility of cure
-
5:31
stem cell redux 2022
-
1:46
personalized treatments to manage post-transplantation outcomes in aml: insights from morpho
-
9:58
the management & optimization of car t-cell therapy in myeloma
-
1:36
the relevance of sct in multiple myeloma
-
2:39
a look into the future of multiple myeloma treatment: t-cell redirecting therapies vs autohsct
-
4:30
next steps for myeloma research and treatment
-
1:19
barriers to accessing reni-cel for the treatment of scd
-
2:55
using mrd to guide treatment decisions during sct in multiple myeloma
-
0:41
mechanism of action of the tri-specific t-cell activating construct hpn217 in r/r multiple myeloma
-
1:48
investigating the role of the stromal niche in the development of myeloma
-
3:01
treatment approaches for asct-eligible myeloma patients in the frontline
-
1:17
adult stem cell transplantation for the treatment of scd
-
4:45
a first-in-human trial of linvoseltamab (regn5458) in r/r myeloma: updated phase i data